Piloting a Culturally Adapted Suicide Prevention for Black Students in Chicago
Launched by UNIVERSITY OF CHICAGO · Aug 8, 2025
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is testing a new version of a suicide prevention program specially designed for Black middle school students in Chicago. Suicide has been a serious problem for Black youth for many years, and this study aims to better understand how issues like racial identity and experiences with discrimination affect their mental health and risk of suicide. The program will be adapted to include these important topics, and the study will see if this approach helps reduce thoughts of suicide, plans, or attempts among students.
Students who are in 6th, 7th, or 8th grade at participating schools and identify as Black may be eligible to join. Participants will take part in the program and complete surveys before, right after, and three months following the program to track any changes in their feelings and behaviors related to suicide. The information gathered will help improve suicide prevention efforts for Black youth and could be used in other schools across the country.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Enrolled in 6th, 7th, or 8th grade at a participating school
- Exclusion Criteria:
- • Not enrolled in 6th, 7th, or 8th grade at a participating school
About University Of Chicago
The University of Chicago is a prestigious research institution renowned for its commitment to advancing medical science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, the University actively engages in cutting-edge research across various therapeutic areas. Its dedicated team of experienced investigators and state-of-the-art facilities enable the University of Chicago to conduct rigorous clinical studies aimed at improving patient outcomes and translating scientific discoveries into tangible healthcare solutions. The institution prioritizes ethical standards and patient safety, ensuring that all trials adhere to the highest regulatory guidelines and best practices in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Janelle R. Goodwill, PhD
Principal Investigator
University of Chicago
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported